NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.2022
- PMID: 35545171
- DOI: 10.6004/jnccn.2022.0026
NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.2022
Abstract
The NCCN Guidelines for Hematopoietic Growth Factors provide recommendations for the appropriate use of growth factors in the clinical management of febrile neutropenia (FN), chemotherapy-induced thrombocytopenia (CIT), and chemotherapy-induced anemia (CIA). Management and prevention of these sequelae are an integral part of supportive care for many patients undergoing cancer treatment. The purpose of these guidelines is to operationalize the evaluation, prevention, and treatment of FN, CIT, and CIA in adult patients with nonmyeloid malignancies and to enable the patient and clinician to assess management options for FN, CIT, and CIA in the context of an individual patient's condition. These NCCN Guidelines Insights provide a summary of the important recent updates to the NCCN Guidelines for Hematopoietic Growth Factors, with particular emphasis on the incorporation of a newly developed section on CIT.
Similar articles
-
NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020.J Natl Compr Canc Netw. 2020 Jan;18(1):12-22. doi: 10.6004/jnccn.2020.0002. J Natl Compr Canc Netw. 2020. PMID: 31910384
-
Cancer- and chemotherapy-induced anemia.J Natl Compr Canc Netw. 2012 May;10(5):628-53. doi: 10.6004/jnccn.2012.0064. J Natl Compr Canc Netw. 2012. PMID: 22570293
-
Current and future use of hematopoietic growth factors in cancer medicine.Hematol Oncol. 2004 Sep;22(3):121-34. doi: 10.1002/hon.736. Hematol Oncol. 2004. PMID: 15991222 Review.
-
Managing hematologic toxicities.J Support Oncol. 2004 Jan-Feb;2(1):65-79. J Support Oncol. 2004. PMID: 15330374 Review.
-
Hematopoietic growth factors as supportive therapy for cancer- and chemotherapy-induced conditions.Curr Opin Oncol. 1991 Aug;3(4):648-55. Curr Opin Oncol. 1991. PMID: 1932223 Review.
Cited by
-
Cost-effectiveness analysis of trifluridine/tipiracil in the treatment of heavily pretreated metastatic gastric cancer from the perspective of Chinese healthcare system.BMJ Open. 2024 Nov 7;14(11):e080846. doi: 10.1136/bmjopen-2023-080846. BMJ Open. 2024. PMID: 39510786 Free PMC article.
-
Chemotherapy-induced febrile neutropenia followed by acute hepatitis E virus infection in rectal cancer patient with synchronous liver and lung metastasis: a case report.BMC Infect Dis. 2025 May 13;25(1):693. doi: 10.1186/s12879-025-11097-w. BMC Infect Dis. 2025. PMID: 40361031 Free PMC article.
-
Telpegfilgrastim for chemotherapy-induced neutropenia in patients with non-small cell lung cancer: a multicentre, randomized, phase 3 study.BMC Cancer. 2025 Mar 17;25(1):490. doi: 10.1186/s12885-025-13736-6. BMC Cancer. 2025. PMID: 40098083 Free PMC article. Clinical Trial.
-
Severe thrombocytopenia induced by niraparib in ovarian cancer patients: a case report and literature review.Front Oncol. 2025 Jul 4;15:1542646. doi: 10.3389/fonc.2025.1542646. eCollection 2025. Front Oncol. 2025. PMID: 40687421 Free PMC article.
-
Outcomes in Patients With Curative Malignancies Receiving Filgrastim as Primary Prophylaxis.Fed Pract. 2023 May;40(Suppl 1):S54-S59. doi: 10.12788/fp.0327. Epub 2022 Nov 17. Fed Pract. 2023. PMID: 37727832 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous